A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
| Excerpt | Reference |
|---|
| "Mesothelioma is an uncommon neoplastic condition." | ( Das, PB; Deodhare, SG; Fletcher, AG, 1976) |
| "Diffuse malignant mesothelioma is a rare tumor in the general population, yet is unique in that it is caused almost exclusively by exposure to asbestos with long-term latency (15 years and over)." | ( Suzuki, Y, 1992) |
| "Mesothelioma is a tumor of the serous surfaces in the thorax and abdomen." | ( Ekman, A; Hand, AM; Husgafvel-Pursiainen, K; Linnainmaa, K; Mattson, K; Mattson, M; Pelin, K; Suitiala, T; Vallas, M, 1992) |
| "Malignant mesothelioma is a highly treatment-resistant neoplasm." | ( Balcerzak, SP; Berenberg, JL; Keppen, MD; Metch, B; Militello, L; Pierce, HI; Zidar, BL, 1992) |
| "Diffuse malignant mesotheliomas are known to secrete a large amount of hyaluronate, whereas adenocarcinomas produce predominantly neutral mucins." | ( Azumi, N; Kagan, E; Sheibani, K; Underhill, CB, 1992) |
| "The situation for mesothelioma is uncertain." | ( Churg, AM; Warnock, ML, 1981) |
| "Mesothelioma is a rare neoplasm in the general population, but it is strongly associated with previous asbestos exposure." | ( Bolinder, E; Boman, G; Fischbein, A; Rohl, AN; Schubert, V; Svane, B; Westerholm, P, 1982) |
| "Pleural mesotheliomas are usually reported after a long interval has passed since first exposure to asbestos." | ( Andrion, A; Mollo, F; Piolatto, G; Scansetti, G; Tiberi, G, 1984) |
| "Malignant mesothelioma is an uncommon, but increasingly important, neoplasm." | ( Buffler, PA; Greenberg, SD; Peterson, JT, 1984) |
| "Malignant mesothelioma is being increasingly recognized in Minnesota and has a grim prognosis in spite of doxorubicin therapy." | ( Iannucci, AM; Kennedy, BJ; Schultz, SM; Vogelzang, NJ, 1984) |
| "A case of malignant mesothelioma is presented with marked radionuclide accumulation in the periphery of the hemithorax on Ga-67 imaging." | ( Carter, JE; Joo, KG; Seo, IS, 1980) |
| "Peritoneal mesotheliomas are rare in women, compared to serous epithelial neoplasms with which they are often confused." | ( Goldblum, J; Hart, WR, 1995) |
| "Malignant mesothelioma is an aggressive tumor, usually induced by asbestos exposure, that has a poor prognosis and is unresponsive to conventional therapy." | ( Bielefeldt-Ohmann, H; Fitzpatrick, DR; Jarnicki, AG; Marzo, AL; Musk, AW; Robinson, BW, 1995) |
| "Although malignant mesothelioma is refractory to current therapies, its localized nature and the accessibility of the pleural space make it a potential target for a similar type of in vivo gene therapy using adenovirus." | ( Albelda, SM; Amin, KM; Davidson, BL; Eck, SL; Elshami, AA; Hwang, HC; Kaiser, LR; Smythe, WR; Wilson, JM, 1995) |
| "Mesothelioma is a malignant tumor of the serous surfaces in the thorax and abdomen, which has proved exceptionally resistant to treatment." | ( Hand, A; Linnainmaa, K; Mattson, K; Pelin, K, 1995) |
| "Pleural mesothelioma is a very rare neoplasm." | ( Blady-Kotela, A; Kotela, I, 1994) |
| "Mesotheliomas are rare." | ( Elmes, P, 1994) |
| "Malignant mesothelioma is a tumour which is generally resistant to chemotherapy." | ( Byrne, M; Musk, AW; Robinson, BW; Upham, JW; van Hazel, G, 1993) |
| "The malignant mesothelioma is characteristic of its polymorphism and the clear cancernation of mesothelial cells." | ( Liu, X; Luo, S; Wang, C, 1993) |
| "Mesotheliomas are discussed as is the role of monoclonal antibodies in diagnosis." | ( Yesner, R, 1993) |
| "Malignant mesothelioma is an uncommon and usually fatal cancer, for which there is no standard treatment." | ( Rusch, VW, 1993) |
| "Malignant mesothelioma is a disease that is refractory to chemotherapy." | ( Antman, KH; Cirrincione, C; Citron, ML; Corson, JM; Green, MR; Harmon, DC; Herndon, JE; Suzuki, Y; Yogelzang, NJ, 1997) |
| "Malignant mesothelioma is one of the very few extrarenal neoplasms in which the Wilms tumor suppressor gene (wt1) is expressed." | ( Kleymenova, EV; LaBate, ME; Walker, CL; Yuan, X, 1998) |
| "Malignant pleural mesothelioma is a fatal neoplasm that is unresponsive to standard modalities of cancer therapy." | ( Albelda, SM; Amin, KM; Coonrod, L; Kaiser, LR; Knox, L; Litzky, LA; Molnar-Kimber, K; Recio, A; Sterman, DH; Treat, J; Wilson, JM, 1998) |
| "Malignant mesothelioma is a clinically aggressive tumor and has a poor prognosis; therefore, the selection of therapeutic strategies is important to improve the prognosis." | ( Fujino, K; Iwahashi, M; Mizobata, S; Nagai, Y; Nanjo, K; Tani, M; Tanimura, H; Tsunoda, T; Ura, K; Wakasaki, H; Yamamoto, M; Yamaue, H; Yukawa, S, 1998) |
| "Localized malignant mesothelioma is an extremely rare form of presentation of malignant mesotheliomas." | ( Hicken, WJ; Mech, K; Ojeda, HF, 1998) |
| "Peritoneal mesothelioma is a rare malignant neoplasm that might be linked to chronic peritoneal inflammation." | ( Belange, G; Chaouat, D; Chaouat, Y; Gompel, H, 1998) |
| "Malignant mesothelioma is a tumor of the pleura for which there is no satisfactory treatment." | ( Byrne, P; Freeman, SM; Gaumer, R; Harrison, L; Kolls, JK; Marrogi, A; Ramesh, R; Schwarzenberger, P; Summer, W; Theodossiou, C; Weinacker, A, 1998) |
| "Malignant pleural mesothelioma is an ideal model for testing new locoregional multimodality approaches because of its aggressive local behavior." | ( Alloisio, A; Civalleri, D; De Cian, F; Esposito, M; Ratto, GB; Spessa, E; Vannozzi, MO, 1999) |
| "Malignant pleural mesothelioma is associated with a poor prognosis because of its resistance to treatment." | ( Astoul, P; Boutin, C; Kasseyet, S, 1999) |
| "Thus, the risk of mesothelioma is 135-times and 1,336-times greater in males and females, respectively, than for the same sex and age groups in Sweden." | ( Hillerdal, G; Metintas, M; Metintas, S, 1999) |
| "Malignant mesothelioma is a rare malignancy with a median survival, ranging from 4 to 18 months in untreated patients." | ( Andersen, MK; Damgaard, K; Krarup-Hansen, A; Mårtensson, G; Olling, S; Thylen, A; Wallin, J; Winther-Nielsen, H, 1999) |
| "Primary peritoneal mesothelioma is a locally aggressive disease that is difficult to treat or even palliate." | ( Alexander, HR; Bartlett, DL; Kranda, KC; Libutti, SK; Park, BJ; Royalty, D; Wu, P, 1999) |
| "Human malignant mesotheliomas are induced almost exclusively by fibrous dusts." | ( Abel, J; Dehnen, W; Roller, M; Sandhu, H; Unfried, K, 2000) |
| "Malignant mesothelioma is a rare tumor in childhood." | ( Fletcher, BD; Haliloglu, M; Hoffer, FA, 2000) |
| "Malignant mesothelioma is a resistant tumor with high levels of manganese superoxide dismutase, a central superoxide scavenging AOE." | ( Kaarteenaho-Wiik, R; Kahlos, K; Kinnula, VL; Linnainmaa, K; Pääkkö, P; Soini, Y; Sormunen, R, 2001) |
| "Malignant mesothelioma is almost invariably fatal." | ( Girling, DJ; Lobban, D; Muers, MF; Qian, W, 2002) |
| "Malignant pleural mesothelioma is a notoriously chemoresistant tumour." | ( Baas, P; Burgers, JA; de Bruin, HG; de Jonge, MJ; Manegold, Ch; Mooi, WJ; Schouwink, JH; van Haarst, JM; van Klaveren, RJ; van Meerbeeck, JP, 2002) |
| "Benign mesothelioma is a rare tumor nearly always find in relation to the genital tract." | ( Aubard, Y; Fermeaux, V; Gilquin, M; Labrousse, F; Roux, J, 2002) |
| "Mesotheliomas are tumors arising from mesothelial cells and are associated with asbestos exposure and approximately 50% contain simian virus 40 (SV40) DNA sequences." | ( Bocchetta, M; Carbone, M; Gazdar, AF; Minna, JD; Shivapurkar, N; Toyooka, KO; Toyooka, S, 2002) |
| "Mesothelioma is a fatal tumor resistant to all treatment modalities for reasons that are still unresolved." | ( Järvinen, K; Kahlos, K; Kinnula, VL; Soini, Y, 2002) |
| "Malignant pleural mesothelioma is an aggressive primary neoplasm for which early detection and accurate staging are known diagnostic challenges." | ( Britz-Cunningham, S; Di Carli, MF; Gerbaudo, VH; Mauceri, C; Sugarbaker, DJ; Treves, ST, 2002) |
| "Malignant pleural mesothelioma is a rare and aggressive tumor characterized by rapid progression, late metastases, and poor prognosis." | ( Jablons, DM; Li, K; Li, L; McCormick, F; Uematsu, K; Xia, C; Xu, Z; You, L; Yuan, X, 2002) |
| "Malignant mesothelioma is an aggressive malignancy that may be caused by environmental carcinogens (asbestos and erionite), viruses (SV40), and genetic predisposition." | ( Vogelzang, NJ, 2002) |
| "Malignant mesothelioma is a highly aggressive tumour." | ( Klominek, J; Liu, Z, 2003) |
| "Desmoplastic mesothelioma is a rare subtype of diffuse malignant mesothelioma, and is often difficult to distinguish from reactive pleural fibrosis because of associated extensive collagen fibrosis." | ( Fujita, M; Ishikawa, R; Itoh, T; Jin, M; Kikuchi, E; Kikuchi, H; Nagashima, K; Sawa, H, 2003) |
| "Malignant mesothelioma is a cancer with poor prognosis associated with exposures to asbestos." | ( Land, S; Martinelli, M; Mossman, BT; Ramos-Nino, ME; Scapoli, L, 2003) |
| "Malignant mesothelioma is a uniformly fatal cancer of the pleural and peritoneal spaces." | ( Albelda, SM; Amin, KM; Friedberg, J; Johnson, SW; Kaiser, LR; Kucharczuk, JC; Litzky, LA; Malden, LD; Matzie, K; Singhal, S; Wiewrodt, R, 2003) |
| "Mesothelioma is a rare neoplasm of the serosal membranes." | ( Livasy, CA; Maygarden, SJ; Tishko, DJ, 2003) |
| "Peritoneal mesothelioma is a rare malignancy that is seen in patients exposed to asbestos or in young women with no known exposure to asbestos." | ( Deavers, M; Hunt, K; Le, DT; Malpica, A; Verschraegen, CF, 2003) |
| "Malignant pleural mesothelioma is an aggressive neoplasm with a highly variable course." | ( Britz-Cunningham, S; Gerbaudo, VH; Sugarbaker, DJ; Treves, ST, 2003) |
| "Mesothelioma are primary malignant neoplasms of the serous membranes." | ( Dalquen, P; Langer, I; Marti, WR; Oertli, D; Rosenthal, R, 2003) |
| "The incidence of mesothelioma is rising rapidly in the UK." | ( Girling, DJ; Hodson, A; Muers, MF; O'Brien, ME; Parmar, MK; Qian, W; Rudd, RM, 2004) |
| "Malignant mesothelioma is a fatal type of neoplasia of the pleura and the peritoneum with currently no known cure." | ( Gellert, N; Neuzil, J; Procopio, A; Tomasetti, M, 2004) |
| "Malignant pleural mesothelioma is an aggressive but rare malignancy with a dismal prognosis." | ( Green, MR; Meyer, ML; Suwanrusme, H, 2004) |
| "Malignant mesothelioma is an uncommon malignancy that is locally invasive and rapidly fatal." | ( Gadgeel, SM; Pass, HI, 2004) |
| "A characteristic of mesothelioma is that there is a long latency period (20-30 years) before the signs and symptoms of the disease become apparent." | ( Chyczewska, E; Chyczewski, L; Laudanski, J; Naumnik, W; Niklinska, W; Niklinski, J; Pluygers, E, 2004) |
| "Malignant mesothelioma is a devastating disease with an onset 20 to 60 years after exposure to asbestos." | ( Kindler, HL, 2004) |
| "Malignant mesothelioma is a rare tumor arising from the pleura or peritoneum." | ( Hamakawa, H; Nakashiro, K; Shintani, S; Terakado, N, 2004) |
| "Malignant pleural mesothelioma is an aggressive malignancy which is almost always fatal; median survival is usually < 1 year." | ( Alvarez, JM; Byrne, MJ; Millward, MJ; Nowak, AK; Robinson, BW, 2004) |
| "Malignant Pleural Mesothelioma is regarded as a tumour, which lacks chemo-sensitivity." | ( Hobrack, E; Jehle, P; Nagel, S; Schütte, W, 2005) |
| "Malignant pleural mesothelioma is notoriously refractory to aggressive multimodality therapy." | ( Alleva, AM; Cole, GW; Maxhimer, JB; Nguyen, DM; Reddy, RM; Schrump, DS; Zuo, J, 2005) |
| "Diffuse pleural mesothelioma is a rare condition with a poor prognosis." | ( Futagawa, T; Izumi, H; Miyamoto, H; Oh, T; Sonobe, S; Yamazaki, A, 2005) |
| "Pleural malignant mesothelioma is a locally aggressive tumor of mesothelial cell origin." | ( Black, JL; Bubendorf, L; Burgess, JK; Gencay, MM; Parson, H; Robinson, BW; Roth, M; Tamm, M; Zhong, J, 2006) |
| "Malignant mesothelioma is an increasingly common tumor with an almost 100% mortality rate." | ( Dobra, K; Gulyás, M; Hjerpe, A; Sun, X, 2006) |
| "Peritoneal mesothelioma is a rare disease with few therapeutic options." | ( Brigand, C; Gilly, FN; Glehen, O; Isaac, S; Mohamed, F; Monneuse, O; Sayag-Beaujard, AC, 2006) |
| "Malignant mesothelioma is a relatively rare tumor that originates in the pleural space and almost invariably results from exposure to asbestos." | ( Clarke, CP; Daniel, FJ; Knight, SR; Seevanayagam, S, 2006) |
| "Malignant mesothelioma is a rare but notoriously chemoresistant tumor." | ( Akbulut, H; Büyükçelik, A; Demirkazik, A; Dinçol, D; Gören, D; Içli, F; Mousa, U; Onur, H; Senler, FC; Utkan, G; Yalçin, B, 2006) |
| "Malignant mesothelioma is known to have a poor prognosis." | ( Higashimoto, M; Maeda, S; Maemura, M; Nagata, K; Noguchi, T; Noma, H; Ogura, O; Takebayashi, Y, 2006) |
| "Malignant mesothelioma is a devastating disease with a poor prognosis." | ( Frizelle, S; Jacobson, BA; Kratzke, RA; Maddaus, MA; Patel, MR; Whitson, BA; Yee, D, 2006) |
| "Mesothelioma is a cancer that originates in the pleura or, more rarely, the peritoneum, and is almost always due to exposure to asbestos fibres." | ( , 2006) |
| "Mesothelioma is a neoplasm of the pleura that is currently incurable by conventional therapies." | ( Cao, X; Littlejohn, J; Morgan, CD; Rodarte, C; Smythe, WR; Zhang, L, 2007) |
| "Malignant mesothelioma is a cancer which is refractory to current treatments." | ( Barbone, D; Bertino, P; Busacca, S; Favoni, R; Gaudino, G; Germano, S; Mutti, L; Pinato, S; Porta, C; Tassi, G, 2007) |
| "The prognosis of mesothelioma is poor and there is no effective treatment at present." | ( Abe, M; Hagiwara, Y; Hino, O; Horikoshi-Sakuraba, Y; Ikesue, M; Kajino, K; Kon, S; Kuwahara, M; Maeda, M; Mitani, H; Nakaishi, M; Segawa, T; Wang, T; Yokoyama, M, 2007) |
| "Malignant mesothelioma is a relatively uncommon malignancy, but continues to increase in incidence in many countries around the world, including Australia." | ( Beer, TW; Heenan, PJ, 2007) |
| "Primary pericardial mesothelioma is a rare clinical entity; about 150 cases have been described in literature." | ( Baga, R; Castañer, E; Montesinos, J; Santos, C; Sole, JM, 2008) |
| "Malignant Mesothelioma is an uncommon and very aggressive tumor that accounts for 1% of all the deaths secondary to malignancy in humans." | ( Baldi, A; Caruso, G; Citro, G; Crispi, S; Scarabello, A; Spugnini, EP, 2008) |
| "Peritoneal mesothelioma is a rare and often aggressive malignancy, mostly affecting asbestos exposed adults." | ( Cioffredi, LA; Jackman, DM; Jänne, PA, 2009) |
| "Malignant pleural mesothelioma is an aggressive cancer." | ( Hughes, A; Li, L; Razak, AR, 2009) |
| "Peritoneal mesothelioma is a rapidly progressing malignancy with a median survival of 6-12 months." | ( Chua, TC; Morris, DL; Yan, TD, 2009) |
| "Malignant mesothelioma is an aggressive cancer with no effective treatment options." | ( Ando, A; Hagiwara, K; Harada, K; Kashiwagi, K; Kido, W; Virgona, N; Yano, T; Yano, Y, 2009) |
| "Malignant mesothelioma is an asbestos-related, aggressive tumour, resistant to most anticancer therapies." | ( Aceto, N; Barbone, D; Bertino, P; Gaudino, G; Manzo, L; Mutti, L; Porta, C; Tassi, G, 2009) |
| "Malignant pleural mesothelioma is a difficult disease to accurately stage." | ( Aubry, MC; Aughenbaugh, GL; Jett, JR; Nichols Iii, FC; Peller, PJ; Subramaniam, RM; Wilcox, BE, 2009) |
| "Peritoneal mesothelioma is one of the peritoneal surface malignancies where long-term survival is a reality after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)." | ( Akther, J; Chua, TC; Morris, DL; Yao, P, 2010) |
| "Malignant Mesothelioma is a rare primary neoplasm affecting the serosal membranes." | ( Davidson, NG; Elbahaie, AM; Kamel, DE; Lawrence, J, 2009) |
| "Malignant pleural mesothelioma is a frequently fatal disease and the impact of available treatments is globally poor." | ( Alifano, M; Camilleri-Broet, S; Dupouy, S; Forgez, P; Loi, M; Régnard, JF, 2010) |
| "Mesothelioma is an uncommon malignancy whose global incidence continues to rise." | ( Kosuri, KV; Otterson, GA; Villalona-Calero, MA; Wang, L; Wu, X, 2010) |
| "Mesothelioma is a malignant tumour of the pleura or peritoneum caused by asbestos." | ( Rudd, RM, 2010) |
| "Malignant mesothelioma is a highly aggressive form of cancer." | ( Arano, Y; Fujibayashi, Y; Fukumura, T; Hino, O; Koizumi, M; Saga, T; Sogawa, C; Sudo, H; Sugyo, A; Tsuji, AB; Uehara, T; Yoshida, C; Yoshii, Y, 2010) |
| "Malignant pleural mesothelioma is on a continuous rise throughout the Western countries." | ( Bruch, HP; Hoffmann, M; Kujath, P; Limmer, S, 2010) |
| "Malignant mesothelioma is an asbestos-related fatal disease with no effective cure." | ( Hamada, H; Kubota, S; Satoh, K; Satoh, M; Sekido, Y; Takemura, Y, 2010) |
| "Malignant mesothelioma is an aggressive cancer that does not respond to standard therapies the cells of which are considered to be highly resistant to apoptosis." | ( Buommino, E; Ciavatta, ML; De Filippis, A; Menegozzo, M; Menegozzo, S; Nicoletti, R; Paoletti, I; Tufano, MA, 2010) |
| "Pleural mesothelioma is an extremely rare neoplasm." | ( Bednarenko, M; Kotela, I; Kotela, P; Laskowicz, K; Wilk-Frańczuk, M; Wołowiec, B, 2010) |
| "Malignant mesothelioma is an aggressive tumor of serosal surfaces, which is refractory to current treatment options." | ( Eguchi, R; Fujimori, Y; Fukuoka, K; Kuribayashi, K; Nakano, T; Ohta, T; Tabata, C; Takeda, H, 2011) |
| "Malignant mesothelioma is an aggressive cancer of the pleura with poor prognosis." | ( Keski-Oja, J; Kinnula, VL; Koli, K; Lindholm, P; Myllärniemi, M; Salmenkivi, K; Soini, Y; Vehviläinen, P, 2011) |
| "Mesothelioma is a "new" malignant disease strongly associated with exposure to amphibole asbestos exposure (amosite and crocidolite) environmentally and in the work place." | ( Craighead, JE, 2011) |
| "Malignant mesothelioma is a rare cancer caused by exposure to asbestos." | ( Gillis, A; Lee, E; Wang, H; Wu, J; Ye, F; Zhang, DY; Zhang, F; Zhao, C, 2011) |
| "Malignant pleural mesothelioma is a highly aggressive cancer with poor prognosis." | ( Anraku, M; de Perrot, M; Rey-McIntyre, K; Tagawa, T; Wu, L; Yun, Z, 2011) |
| "Malignant pleural mesothelioma is a fatal malignancy linked to asbestos exposure." | ( Brancato, V; Buommino, E; Ciavatta, ML; De Filippis, A; Donnarumma, G; Menegozzo, M; Menegozzo, S; Nicoletti, R; Rizzo, A; Tufano, MA, 2012) |
| "Peritoneal mesothelioma is a rare form of malignant mesothelioma, making up <30% of diagnosed mesothelioma cases." | ( Conversano, A; D'Abbicco, D; Epifania, BR; Indellicato, R; Margari, A, 2012) |
| "Malignant pleural mesothelioma is known to be widely resistant to therapy and new treatment strategies are needed." | ( Asakura, K; Fukutomi, T; Izumi, Y; Kawai, K; Nomori, H; Serizawa, A; Suematsu, M; Wakui, M; Yamauchi, Y, 2011) |
| "Malignant pleural mesothelioma is known to be widely resistant to therapy, and new treatment strategies are needed." | ( Adachi, T; Asakura, K; Izumi, Y; Kawai, K; Kawamura, M; Mizushima, T; Nakamura, M; Nomori, H; Ohmura, M; Serizawa, A; Suematsu, M; Wakui, M; Yamamoto, M; Yamauchi, Y, 2011) |
| "Malignant pleural mesothelioma is a fatal neoplasm related to asbestos exposure." | ( Belcher, E; Bille, A; Cane, P; Landau, D; Lang-Lazdunski, L; Spicer, J; Steele, J; Taylor, H, 2011) |
| "Mesothelioma is an incurable cancer of the pleura with a life expectancy of less than 1 year." | ( Byrne, P; Gaumer, R; Harrison, L; Kolls, JK; Marrogi, A; Norton, J; Schwarzenberger, P, 2011) |
| "Malignant mesothelioma is an aggressive malignancy related to asbestos and erionite exposure." | ( Carbone, M; Yang, H, 2012) |
| "Malignant mesothelioma is known for its dismal prognosis and poor response to conventional treatment." | ( Burgers, JA; Damhuis, RA; Schroten, C, 2012) |
| "Mesothelioma is a rare malignancy of the pleura with limited therapeutic options." | ( Krug, LM; Zauderer, MG, 2012) |
| "Malignant mesothelioma is an aggressive tumor arising from mesothelial cells of serous membranes." | ( Eguchi, R; Fujimori, Y; Kubo, S; Nakano, T; Ogawa, H; Ohta, T; Tabata, C; Takeda, H, 2012) |
| "Malignant pleural mesothelioma is known to be widely resistant to therapy and new treatment strategies are needed." | ( Asakura, K; Hayashi, Y; Izumi, Y; Nomori, H; Yamauchi, Y, 2012) |
| "Malignant pleural mesothelioma is a rare malignancy with a dismal prognosis." | ( Grosso, F; Scagliotti, GV, 2012) |
| "Peritoneal mesothelioma is a rare and aggressive tumor." | ( Alexander, HR; Cao, Q; Chen, W; Dilsizian, V; Hausner, PF; Heath, J; Lu, M, 2012) |
| "Primary pericardial mesothelioma is an extremely rare malignancy." | ( Aga, F; Nishiyama, Y; Norikane, T; Yamamoto, Y, 2012) |
| "Malignant pleural mesothelioma is a rare tumour." | ( Graziano, V; Lisi, R; Parisi, A; Raffetto, N; Resuli, B; Takanen, S; Tombolini, V, 2012) |
| "Peritoneal mesothelioma is a rare malignancy where life expectancy with systemic chemotherapy remains poor." | ( Chong, CH; Chua, TC; Morris, DL, 2012) |
| "Lung cancer and mesothelioma are malignant tumors with generally dismal prognosis and therefore palliative pain treatment constitutes a challenge for the clinician." | ( Kaasa, S; Klepstad, P; Kloke, M; Salminen, EK; Silvoniemi, M; Syrjänen, K, 2013) |
| "Malignant pleural mesothelioma is a poorly responsive tumor known to overexpress the phase II detoxification enzyme glutathione-S-transferase, which catalyzes the conjugation between glutathione and platinum(II)-containing drugs." | ( Alama, A; Caccuri, AM; Cicconi, R; De Luca, A; Federici, G; Palumbo, C; Pastore, A; Pellizzari Tregno, F; Sau, A, 2013) |
| "Peritoneal mesothelioma is an aggressive malignancy which is indeed very rare." | ( Gilani, SN; Gridley, R; Jegannathen, A; Searle, G, 2013) |
| "Malignant pleural mesothelioma is an aggressive tumor that has a poor prognosis and is resistant to unimodal approaches." | ( Adolfo, F; Adriano, P; Anna, C; Federico, R; Francesca, R; Francesco, F; Gbenga, K; Gino, C; Giuseppe, M; Lorenzo, S; Martino, DT; Matteo, C; Paolo, M, 2013) |
| "Malignant mesothelioma is a devastating disease with a need for new treatment strategies." | ( Beuschel, SL; Cason, C; Hillegass, J; MacPherson, MB; Miller, JM; Mossman, BT; Pass, HI; Sayan, M; Shukla, A; Vacek, PM, 2013) |
| "Malignant mesothelioma is a highly aggressive tumor arising from mesothelial-lined surfaces, most often in the pleura cavities." | ( Gülly, C; Halbwedl, I; Hatz, M; Kollmeier, J; Mairinger, F; Mairinger, T; Popper, H; Quehenberger, F; Roth, A; Stacher, E; Stephan-Falkenau, S; Vollbrecht, C, 2013) |
| "The incidence of mesothelioma is rising." | ( Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z, 2013) |
| "Malignant pleural mesothelioma is strongly dependent on vasculature with high vessel counts and high concentrations of serum vascular growth factors." | ( Baas, P; Buikhuisen, WA; Burgers, JA; Custers, FL; Gans, SJ; Groen, HJ; Korse, CM; Nowak, AK; Pavlakis, N; Schouwink, JH; Schramel, FM; Strankinga, WF; van Klaveren, RJ; Vincent, AD, 2013) |
| "Mesothelioma is a rare neoplasm arising from mesothelial surfaces with the malignant pleural mesothelioma (MPM) as the most common form." | ( Akca, Z; Aksahin, A; Aslan, T; Berk, V; Buyukcelik, A; Erden, A; Karaca, H; Mutlu, H; Ozkan, M, 2013) |
| "Malignant mesothelioma is one of the most aggressive forms of cancer known." | ( Castranova, V; Dinu, CZ; Liu, Y; Lohcharoenkal, W; Rojanasakul, Y; Stueckle, TA; Wang, L, 2013) |
| "Mesothelioma is often diagnosed in an advanced stage, for which no effective therapeutic protocols are yet established." | ( Chew, SH; Misawa, N; Nagai, H; Okazaki, Y; Toyokuni, S; Yasui, H, 2013) |
| "The incidence of mesothelioma is increasing." | ( Anderson, J; Clague, H; Murphy, S; Pollock, S; Probert, G; Sridharan, K; Taylor, I, 2013) |
| "Mesothelioma is a notoriously chemotherapy-resistant neoplasm, as is evident in the dismal overall survival for patients with those of asbestos-associated disease." | ( Corson, JM; Eilers, G; Fletcher, JA; Kuang, Y; Li, H; Li, X; Liu, L; Meng, F; Ou, WB; Sheng, Q; Shi, S; Yan, Z; Zhou, H; Zhou, S, 2014) |
| "Mesothelioma is principally caused by asbestos and may be preventable because there is a long latent period between exposure and disease development." | ( Alfonso, H; Lake, RA; Musk, AW; Nowak, AK; Olsen, N; Robinson, BW; Robinson, C; Walsh, A; Woo, S, 2014) |
| "Mesothelioma is inherently chemo-resistant with only 50% of patients responding to the standard of care treatments, and consequently it has a very grim prognosis." | ( Clarke, SJ; Harvie, R; Howell, VM; Hudson, AL; Klebe, S; Moon, E; Pavlakis, N; Weir, C, 2014) |
| "Malignant pleural mesothelioma is an aggressive malignancy characterized by frequent resistance to chemo- and radiotherapy, poor outcome, and limited therapeutic options." | ( Berger, W; Dome, B; Filipits, M; Garay, T; Ghanim, B; Grasl-Kraupp, B; Grusch, M; Heffeter, P; Hegedus, B; Hoda, MA; Holzmann, K; Kenessey, I; Klepetko, W; Klikovits, T; Laszlo, V; Marian, B; Münzker, J; Pirker, C; Schelch, K; Selzer, E; Setinek, U; Torok, S; Tovari, J; Wagner, C, 2014) |
| "Malignant pleural mesothelioma is a global health issue." | ( Ho, JC; Lam, SK; Li, YY; Zheng, CY, 2015) |
| "Malignant mesothelioma is an asbestos exposure related tumor affecting mainly pleura and it usually has a dismal prognosis." | ( Koli, K; Myllärniemi, M; Pasternack, A; Ritvos, O; Rönty, M; Sutinen, E; Tamminen, JA; Yin, M, 2015) |
| "Peritoneal mesothelioma is a rare disease with poor prognosis." | ( Cloutier, AS; Drolet, P; Dubé, P; Hubert, J; Sideris, L; Thiboutot, E, 2015) |
| "Malignant mesothelioma is an incurable disease associated with asbestos exposure arising in the pleural cavity and less frequently in the peritoneal cavity." | ( Curioni-Fontecedro, A; Felley-Bosco, E; Peters, S; Petrausch, U; Schmitt-Opitz, I; Stahel, RA; Weder, W, 2015) |
| "Asbestos-induced mesothelioma is a worldwide problem." | ( Nagai, H; Toyokuni, S; Yamashita, K, 2015) |
| "Currently rates of mesothelioma are rising and estimates indicate that the incidence of mesothelioma will peak within the next 10-15 years in the western world, while in Japan the peak is predicted not to occur until 40 years from now." | ( Benedetti, S; Catalani, S; Galati, R; Nuvoli, B, 2015) |
| "Mesothelioma is an aggressive malignancy generally associated with professional exposure to asbestos." | ( Carbone, M; Dey, A; Dixit, V; Flores, EG; Kanodia, S; Kendrick, B; Lapid, D; Larson, D; Napolitano, A; Pass, HI; Pastorino, S; Pellegrini, L; Powers, A; Tanji, M; Yang, H, 2016) |
| "Malignant mesothelioma is an aggressive and therapy-resistant neoplasm arising from mesothelial cells." | ( Fujii, M; Harada, D; Hashida, S; Hotta, K; Isozaki, H; Kato, Y; Kiura, K; Kubo, T; Kudo, K; Minami, D; Ochi, N; Ohashi, K; Sato, A; Tabata, M; Takigawa, N; Tanaka, T; Tanimoto, M; Toyooka, S, 2015) |
| "Malignant mesothelioma is an aggressive tumor arising from mesothelial cells of serous membranes, and forms spheroid-like cell aggregates in pleural and peritoneal effusions." | ( Eguchi, R; Fujimori, Y; Fujita, Y; Nakano, T; Ogawa, H; Tabata, C; Wakabayashi, I, 2015) |
| "Peritoneal mesothelioma is rare, and the sarcomatoid variant is more infrequent, with <30 cases reported to date in the literature." | ( Pavlisko, EN; Roggli, VL, 2015) |
| "Mesothelioma is an aggressive tumor associated with asbestos exposure." | ( Park, WH; You, BR, 2016) |
| "Malignant pleural mesothelioma is an aggressive cancer with poor prognosis, linked to occupational asbestos exposure." | ( Audigier-Valette, C; Corre, R; Creveuil, C; Gervais, R; Gounant, V; Greillier, L; Janicot, H; Lebitasy, MP; Locher, C; Margery, J; Mazieres, J; Milleron, B; Molinier, O; Monnet, I; Morin, F; Moro-Sibilot, D; Parienti, JJ; Rivière, F; Scherpereel, A; Tran, Q; Zalcman, G, 2016) |
| "Mesothelioma is an aggressive tumor which is mainly derived from the pleura of lung." | ( Park, WH; You, BR, 2016) |
| "Malignant Mesothelioma is a highly aggressive cancer, which is difficult to diagnose and treat." | ( Berns, A; Bianchi, ME; Boldorini, R; Ceriotti, C; Crippa, L; Crippa, MP; D'Incalci, M; de Vries, H; Doglioni, C; Frapolli, R; Frenquelli, M; Gatti, E; Marchis, FD; Mezzapelle, R; Moresco, RM; Pecciarini, L; Perani, L; Preti, A; Recordati, C; Rrapaj, E; Scanziani, E; Spinelli, AE; Valtorta, S; Venturini, M, 2016) |
| "Malignant mesothelioma is a rare and aggressive tumor with a poor prognosis." | ( Akin, O; Arslan, A; Deniz, E; Ozcakir-Tomruk, C, 2016) |
| "Malignant mesothelioma is an aggressive disease with dismal prognosis despite multimodal treatment including chemotherapy, surgery and radiotherapy." | ( Cathomas, R; Mark, M; Metaxas, Y; von Moos, R, 2016) |
| "Malignant mesothelioma is a locally aggressive and highly lethal neoplasm of pleural, peritoneal and pericardial mesothelial cells without successful therapy." | ( Ayvali, N; Demiroglu-Zergeroglu, A; Ergene, E; Kuete, V; Sivas, H, 2016) |
| "Mesothelioma is a very aggressive cancer that is brought on by asbestos exposure." | ( Casuccio, A; Degiovanni, D; Mercadante, S, 2016) |
| "Malignant pleural mesothelioma is a clear example of this clinical challenge." | ( Chillura, I; Migliore, M; Milazzotto, R; Militello, C; Pagana, A; Pergolizzi, S; Privitera, G; Raffaele, L; Salamone, V; Spatola, C; Tocco, A, 2016) |
| "Malignant mesothelioma is a rare aggressive solid tumor that is invariably incurable." | ( Igaki, T; Iida, S; Irie, T; Matsumoto, R; Mitachi, K; Miura, T; Miyakawa, T; Ohata, Y; Saitou, K; Shiobara, H; Yamazaki, S, 2016) |
| "Mesothelioma is resistant to conventional treatments and is often defective in p53 pathways." | ( Hiroshima, K; Morinaga, T; Namiki, T; Sekine, I; Shimada, H; Shimazu, K; Shingyoji, M; Tada, Y; Tagawa, M; Tatsumi, K, 2017) |
| "Malignant mesothelioma is an aggressive cancer with limited therapeutic options." | ( Hara, A; Hosono, M; Satoh, T; Sugawara, S; Tatsuta, T, 2017) |
| "Malignant mesothelioma is characterized by a poor prognosis and resistance to conventional therapies." | ( Aerts, JG; Bezemer, K; Dammeijer, F; Hegmans, JP; Hendriks, RW; Kaijen-Lambers, ME; Lievense, LA; van Hall, T; van Nimwegen, M, 2017) |
| "Malignant pleural mesothelioma is an aggressive cancer, characterized by rapid progression and high mortality." | ( Barbieri, F; Carra, E; Daga, A; Favoni, RE; Filiberti, RA; Florio, T; Marubbi, D; Mutti, L; Pattarozzi, A; Würth, R, 2017) |
| "Mesothelioma is a fatal tumor of the pleura and is strongly associated with asbestos exposure." | ( Bennett, J; Bushell, M; Chernova, T; Dinsdale, D; Donaldson, K; Dudek, KM; Galavotti, S; Greaves, P; Grosso, S; Le Quesne, J; MacFarlane, M; Murphy, FA; Nakas, A; Poland, CA; Powley, IR; Schinwald, A; Sun, XM; Willis, AE; Zacarias-Cabeza, J, 2017) |
| "Malignant mesothelioma is difficult to diagnose at an early stage, yet there are no particularly effective treatments available at the advanced stage, thus necessitating efficient strategies to prevent MM in individuals already exposed to asbestos." | ( Chew, SH; Ohara, Y; Okazaki, Y; Shibata, T; Toyokuni, S; Yamashita, K, 2018) |
| "Pleural mesothelioma is a deadly form of cancer." | ( Briganti, S; Camera, E; Galati, R; Mastrofrancesco, A; Nuvoli, B, 2018) |
| "Malignant mesothelioma is an aggressive cancer that results from exposure to asbestos." | ( Hara, A; Hosono, M; Satoh, T; Sugawara, S; Tatsuta, T, 2018) |
| "- Although many mesotheliomas are related to asbestos exposure, not all are, and there is increasing information on other causes of mesothelioma." | ( Attanoos, RL; Churg, A; Galateau-Salle, F; Gibbs, AR; Roggli, VL, 2018) |
| "Malignant mesothelioma is an asbestos-related aggressive tumor and current therapy remains ineffective." | ( Hatanaka, K; Kubota, S; Satoh, M; Takemura, Y, 2018) |
| "Malignant mesothelioma is an aggressive cancer with poor prognosis." | ( Joensuu, E; Koli, K; Li, C; Myllärniemi, M; Rezov, V; Rönty, M; Vartiainen, V; Yin, M, 2018) |
| "Human pleural mesothelioma is an incurable and chemoresistant cancer." | ( Cavin, S; Dyson, PJ; Krueger, T; Liaudet, L; Perentes, JY; Riedel, T; Ris, HB; van den Bergh, H, 2018) |
| "Mesothelioma is perhaps the most widely recognised; however, there are many others that are more common and should be considered." | ( Aluja Jaramillo, F; Bhalla, S; Gutierrez, F, 2018) |
| "Malignant pleural mesothelioma is an aggressive cancer with poor prognosis." | ( Cheng, YY; Church, WB; Duff, AP; Håkansson, AP; Howell, VM; Hudson, AL; Knott, RB; Liu, GJ; Pinese, M; Rath, EM; Reid, G; Sarun, KH; Wang, YD; Weir, C, 2018) |
| "Mesothelioma is a malignant tumor mainly correlated to occupational asbestos exposure." | ( Calligaro, C; Gianoncelli, A; Marcuzzo, T; Melato, M; Pascolo, L; Pascotto, E; Rizzardi, C, 2018) |
| "Malignant mesothelioma is an aggressive fibrous tumor, predominantly of the pleura, with a very poor prognosis." | ( Abayasiriwardana, KS; Birnie, KA; Laurent, GJ; McAnulty, RJ; Mutsaers, SE; Prêle, CM; Robinson, BW; Wood, MK, 2019) |
| "Malignant Mesothelioma is an uncommon tumor that usually presents with diffuse pleural involvement and carries a dismal prognosis." | ( Kalhor, N; Khawar, S; Mann, S; Moran, C, 2019) |
| "Ovarian mesothelioma is a rare and aggressive tumor." | ( Chen, Y; Huang, Z; Sun, R, 2019) |
| "Malignant pleural mesothelioma is a rare disease originating from mesothelial cells of the pleura and is related to asbestos exposure." | ( Corhay, JL; Duysinx, B; Louis, R; Paulus, A; Pellegrini, I; Radermecker, MA; Sibille, A; Vaillant, F, 2019) |
| "Malignant pleural mesothelioma is a lethal malignancy with poor survival and high local recurrence rates despite multimodal therapy with cytoreduction and chemoradiation." | ( Chu, NQ; Colby, A; Colson, YL; de Forcrand, C; Grinstaff, MW; Liu, R; Padera, RF, 2020) |
| "Localized malignant mesothelioma is rare." | ( Cao, J; Chen, Y; Hu, J; Xu, T; Zhang, X, 2020) |
| "Malignant mesothelioma is an aggressive disease for which few effective therapies are available." | ( Ferrarotto, R; Gay, CM; Gibbons, DL; Glisson, BS; Heymach, JV; Kies, MS; Lee, JJ; Lu, W; Simon, GR; Tang, XM; Tsao, AS; Wistuba, II; Zhou, Y, 2020) |
| "Malignant pleural mesothelioma is one of the most aggressive malignancies with a very poor prognosis." | ( Chemotherapy, HII; Chudacek, J; Fischer, O; Hanuliak, J; Klos, D; Lemstrová, R; Report, SCAPOMTOMP; Stasek, M; Szkorupa, M, 2020) |
| "Mesothelioma is a cancer of the lung pleura primarily associated with inhalation of asbestos fibers." | ( Bonner, JC; Sridharan, S; Taylor-Just, A, 2021) |
| "Mesothelioma is a highly aggressive tumour associated with asbestos exposure and is histologically classified into three types: epithelioid-type, sarcomatoid-type and biphasic-type." | ( Abe, M; Denda-Nagai, K; Fujihira, H; Hino, O; Irimura, T; Kajino, K; Matsuda, A; Miyazaki, M; Nakagawa, T; Noji, M; Takakura, D, 2021) |
| "Mesothelioma is a highly aggressive cancer of the mesothelial lining that is caused by exposure to asbestos." | ( Adhikary, G; Eckert, RL; Ezeka, G; Friedberg, JS; Kandasamy, S, 2021) |
| "Mesothelioma is a highly lethal cancer developing in the lung, heart, and abdominal membranes." | ( Cömertpay, S; Delibaş, M; Gül, A; Tekin Turhan, MS, 2022) |
| "Malignant mesothelioma is a rare neoplasm associated with asbestos exposure." | ( Danese, MD; Daumont, M; Gleeson, M; Lubeck, D; Nwokeji, E; Penrod, JR, 2022) |
| "Peritoneal mesothelioma is an aggressive disease with a median survival of under three years, due to a lack of effective treatment options." | ( Bressler, E; Colson, YL; Ekladious, I; Grinstaff, MW; Hung, YP; Liu, R; Martin, A; Neal, EJ; Sabatelle, RC, 2022) |
| "Malignant pleural mesothelioma is a rare type of cancer, whose incidence, however, is increasing and will presumably continue to rise in the coming years." | ( Fendler, WP; Ferdinandus, J; Hautzel, H; Herrmann, K; Maier, S; Metzenmacher, M; Plönes, T; Sandach, P; Seifert, R, 2022) |
| "Localized malignant mesothelioma is a rare disease and little is known about its treatment strategy." | ( Harada, D; Kiriyama, Y; Kozuki, T; Maki, Y; Saeki, K; Shigematsu, H; Suehisa, H; Teramoto, N; Ueno, T; Yamashita, M, 2022) |
| "Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos in many countries, the incidence of malignant pleural mesothelioma failed to decline worldwide." | ( Bazille, C; Bergot, E; Brosseau, S; Dubois, F; Levallet, G; Levallet, J; Madelaine, J; Maille, E; Zalcman, G, 2022) |
| "Malignant mesothelioma is an aggressive tumor originating from the mesothelial cells and presenting in general with a very poor prognosis." | ( Castello, A; Lopci, E; Mansi, L, 2022) |
| "Malignant pleural mesothelioma is a neoplasm involving mesothelial cells of the pleura." | ( García de Lacoba, M; Quijano Moreno, SL, 2022) |
| "Malignant mesothelioma is a rare disease with limited treatment options." | ( Dunne, B; Harden, S; Hoang, W; John, T; Leal, JL; Xue, J, 2022) |
| "Malignant mesothelioma is an aggressive tumour of the pleura (MPM) or peritoneum with a clinical presentation at an advanced stage of the disease." | ( Cabeza, JZ; Cain, K; Chernova, T; Craxton, A; Grosso, S; MacFarlane, M; Nakas, A; Self, EL; Sun, XM; Tenor, AR; Willis, AE, 2022) |
| "Malignant mesothelioma is a rare tumor arising from the mesothelial cells that line the pleura, pericardium, peritoneum, and tunica vaginalis." | ( Ahuja, J; Carter, BW; Gladish, GW; Marom, EM; Shroff, GS; Strange, CD; Truong, MT, 2023) |
| "Malignant mesothelioma is a rare tumor arising from the mesothelial cells that line the pleura, pericardium, peritoneum, and tunica vaginalis." | ( Ahuja, J; Carter, BW; Gladish, GW; Marom, EM; Shroff, GS; Strange, CD; Truong, MT, 2023) |
| "Malignant mesothelioma is a rare tumor arising from the mesothelial cells that line the pleura, pericardium, peritoneum, and tunica vaginalis." | ( Ahuja, J; Carter, BW; Gladish, GW; Marom, EM; Shroff, GS; Strange, CD; Truong, MT, 2023) |
| "Primary malignant mesothelioma is a rarity among malignant liver tumors." | ( Aigner, RM; Brcic, L; Fuchsjäger, M; Pernthaler, B; Talakic, E, 2023) |
| "Primary malignant mesothelioma is a rarity among malignant liver tumors." | ( Aigner, RM; Brcic, L; Fuchsjäger, M; Pernthaler, B; Talakic, E, 2023) |
| "Mesothelioma is an extremely aggressive disease that lacks effective therapy." | ( Adhikary, G; Chen, X; Eckert, RL; Emadi, A; Friedberg, JS; Naselsky, W; Newland, JJ; Shrestha, S; Xu, W, 2023) |
| "Pleural mesothelioma is a rare disease with a dismal prognosis and few therapeutic options." | ( Bertino, P; Bertolotti, M; Boccuzzi, F; Cerbone, L; Cimorelli, A; Crivellari, S; De Angelis, AM; Delfanti, S; Grosso, F; Righi, L, 2023) |
| "Malignant pleural mesothelioma is a pathology with no effective therapy and a poor prognosis." | ( Alessandri, G; Alfieri, R; Bonelli, M; Coccé, V; Flammini, L; Frati, C; Gianni, A; La Monica, S; Lagrasta, CA; Paino, F; Pessina, A; Petrella, F, 2023) |
| "Mesothelioma is characterised by its aggressive invasive behaviour, affecting the surrounding tissues of the pleura or peritoneum." | ( Bosco, A; de Jong, E; Lake, RA; Lansley, SM; Lee, YCG; Lesterhuis, WJ; Orozco Morales, ML; Rinaldi, CA; Zemek, RM, 2023) |
| "Mesothelioma is a neoplastic disease associated with asbestos exposure." | ( Akao, K; Mukai, S; Sato, A; Sato, T; Sekido, Y; Tsujimura, T, 2023) |
| "Malignant mesothelioma is a highly malignant disease that most often occurs in the pleural cavity, followed by the peritoneum and pericardium." | ( Chen, TH; Li, J; Liu, X; Zhang, YL; Zhao, F, 2023) |
| "Four mesotheliomas are reported from this single facility that used chrysotile asbestos automotive products." | ( Frank, AL, 2023) |
| "Malignant mesothelioma is a rapidly lethal cancer that has been increasing at an epidemic rate over the last three decades." | ( Bzura, A; Cave, J; Darlison, L; Dulloo, S; Eminton, Z; Ewings, S; Fennell, D; Griffiths, D; Griffiths, G; Hill, K; Johnson, L; Luo, JL; Mallard, K; Morgan-Fox, A; Nye, M; Poile, C; Spicer, J; Stuart, C; Taylor, P, 2023) |